UroGen Pharma (URGN) Long-Term Deferred Tax (2023 - 2025)

UroGen Pharma (URGN) has 3 years of Long-Term Deferred Tax data on file, last reported at $153.4 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 24.73% year-over-year to $153.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153.4 million (up 24.73% YoY) and the FY2025 annual result came in at $153.4 million, up 24.73% from the prior year.
• Long-Term Deferred Tax rose to $153.4 million in Q4 2025, from $122.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $153.4 million in Q4 2025 to a low of $103.6 million in Q4 2023.
• A 3-year average of $126.6 million and a median of $122.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax rose 18.71% — and 2025, when it rose 24.73%.
• Tracing URGN's Long-Term Deferred Tax over 3 years: stood at $103.6 million in 2023, then climbed by 18.71% to $122.9 million in 2024, then advanced by 24.73% to $153.4 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $153.4 million (Q4 2025), $122.9 million (Q4 2024), and $103.6 million (Q4 2023), per Business Quant data.